AstraZeneca Issues Statement on Competitor to Nexium - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca Issues Statement on Competitor to Nexium



AstraZeneca issued a statement regarding the launch of esomeprazole strontium in the United States by Seoul, South Korea-based Hanmi Pharmaceutical and its US marketing partner Amneal Pharmaceuticals.
 
 Amneal Pharmaceuticals reported that the first shipping of esomeprazole strontium was made to three major US pharmaceutical wholesalers on Dec. 18, 2013. Esomeprazole strontium contains the same active moiety (esomeprazole) in a different salt form as found in AstraZeneca's branded proton-pump inhibitor Nexium (esomeprazole magnesium) and is used to treat adult patients for the short term treatment of gastroesophageal reflux disease (GERD). Hanmi Pharmaceutical received FDA approval for esomeprazole strontium delayed-release capsules for oral use in August 2013.  AstraZeneca's Nexium had 2012 sales of $3.9 billion. 

In a press statement, AstraZeneca said that it "is aware of reports that an 505(b)(2) NDA esomeprazole strontium product has been launched in the US by Hanmi Pharmaceutical and affiliates (Hanmi) and its US marketing partner Amneal Pharmaceuticals (Amneal). 

AstraZeneca said that on Sept. 30, 2013, the US Court of Appeals for the Federal Circuit  (CAFC) lifted a temporary injunction against Hanmi’s US launch of its 505(b)(2) NDA esomeprazole strontium product (previously granted on Sept. 13,  2013). AstraZeneca’s appeal of the lower court’s December 2012 claim construction remains pending. After oral argument on Nov. 18, 2013, a decision is expected from the CAFC in early 2014. 

"Depending on the outcome of the appeal, Hanmi's sales are at risk of owing AstraZeneca patent-infringement damages," said AstraZeneca in its statement. "AstraZeneca’s appeal concerns both patents-at-issue in the patent-infringement litigation against Hanmi (US Patent Nos. 5,714,504 and 5,877,192).  AstraZeneca understands that Hanmi’s 505(b)(2) NDA esomeprazole strontium product is not AB-rated and is not automatically substitutable for Nexium."

AstraZeneca said that the developments have no impact on AstraZeneca’s full-year 2013 financial guidance.

Source:  AstraZeneca and Hanmi Pharmaceutical

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here